- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02651948
Transperineal, MRI-guided, Prostate Biopsy
February 16, 2024 updated by: University Hospital, Strasbourg, France
Transperineal, MRI-guided, Prostate Biopsy: First Step to Focal Treatment of Prostate Cancer
Primary purpose:
Complications and rehospitalizations after transperineal prostate biopsy MRI-guided are reduced than transrectal prostate biopsies.
Secondary purposes:
- Patients tolerance after transperineal prostate biopsy MRI-guided is better than after transrectal prostate biopsies.
- Core of transperineal prostate biopsies are better than core of transrectal prostate biopsies
- Study of correlation between radiologic images and anatomopathologic result
- Description of needle track during the procedure
- Description of real time template saturation prostate biopsy
- Comparison of transperineal prostate biopsy relevance according to EBM
- Comparison of 1.5T MRI and 3T MRI for prostate cancer detection
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
90
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lang Hervé, MD
- Email: herve.lang@chru-strasbourg.fr
Study Contact Backup
- Name: Tricard Thibault
- Email: thibault.tricard@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67000
- Service d'urologie
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion criteria:
- Men
- 40 to 80 years' old
- Affiliation to French social health system
- Signed consent
- Prostate cancer suspicion based on prostate specific antigen (PSA) or digital rectal exam WITH abnormal MRI (Prostate Imaging Reporting and Data System score 3) AND negative transrectal prostate biopsies
- Patient treated by active surveillance for a low risk prostate cancer (T1c or T2a, Gleason = 6, PSA < 10)
Exclusion criteria:
- Gleason > 6 prostate cancer
- Metastatic prostate cancer
- Contraindication to MRI
- Contraindication to general anesthesia
- Non-reversible hemostasis trouble
- Inability to give consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transperineal prostate biopsy (TPB)
Transperineal prostate biopsy MRI-guided
|
|
Active Comparator: Transrectal prostate biopsy (TRB)
Transrectal prostate biopsy echo-guided
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Collection of complications and rehospitalizations by using questionnaire
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2015
Primary Completion (Actual)
August 1, 2023
Study Completion (Actual)
February 1, 2024
Study Registration Dates
First Submitted
December 23, 2015
First Submitted That Met QC Criteria
January 8, 2016
First Posted (Estimated)
January 11, 2016
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 16, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6253
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Transrectal prostate biopsy (TRB):
-
Institut Mutualiste MontsourisUnknownProstate CancerFrance
-
TC Erciyes UniversityCompleted
-
The University of Texas Medical Branch, GalvestonCompletedProstate Cancer | Magnetic Resonance Imaging | Target Lesion | Fusion Biopsy | Clinically Significant Prostate Cancer | TransperinealUnited States
-
Heinrich-Heine University, DuesseldorfGerman Cancer Research CenterUnknown
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingHealthy | Prostate Cancer | Conditions Influencing Health StatusUnited States
-
Queen's UniversityUnknown
-
Rabin Medical CenterUnknown
-
TC Erciyes UniversityCompletedProstate Cancer | Pain Due to Certain Specified Procedures | BiopsyTurkey
-
University of MagdeburgCompleted
-
Spectrum Pharmaceuticals, IncCompletedMetastatic CancerFrance, United States, Canada, Belgium, Italy, Australia, United Kingdom, Germany, Hungary